Company Overview
Pediatrix Medical Group, Inc. operates within the healthcare sector, specifically focusing on the medical care facilities industry by providing specialized newborn, maternal-fetal, and pediatric subspecialty care services throughout the United States. The organization delivers essential clinical care to infants born prematurely or with medical complications, primarily utilizing specific units at hospitals such as neonatal intensive care units (NICUs) to manage complex cases. As of the latest available data, the company holds a market capitalization of $1.69B and generates annual revenue of $1.91B, supported by a workforce of 4,280 employees. These financial figures indicate that the company maintains a substantial operational footprint within the specialized medical care market, reflecting a significant scale relative to its peer group in the medical care facilities sector. The combination of its market cap and revenue stream suggests a stable, established entity that serves a critical niche in the broader healthcare ecosystem, balancing specialized service delivery with a solid financial base.
Financial Health
The company reported a trailing twelve-month revenue of $1.91B, resulting in a net income of $165.39M and an EBITDA of $252.91M. The substantial gap between the $1.91B in revenue and the $165.39M in net income reveals a distinct cost structure where operating expenses and taxes consume approximately 91.4% of top-line sales before reaching the bottom line. Free cash flow stands at $190.33M, which signifies a robust ability to generate liquidity from operations, providing the company with significant financial flexibility to fund capital expenditures or manage operational requirements without relying heavily on external financing. Profitability analysis shows a gross margin of 25.8%, an operating margin of 11.1%, and a profit margin of 8.6%, indicating that the company retains roughly 25.8 cents for every dollar of revenue after direct costs, with only 8.6 cents remaining as final profit after all expenses. On the balance sheet, the company holds $499.72M in cash against $634.61M in total debt, while the debt-to-equity ratio is calculated at 73.29, suggesting a leveraged balance sheet where debt obligations exceed equity capital. Despite the leverage, the current ratio of 1.66 indicates a healthy short-term liquidity position, as current assets are more than 1.5 times current liabilities, ensuring the ability to meet obligations due within a year. Return metrics further illustrate management effectiveness, with a return on equity of 20.3% and a return on assets of 6.6%, demonstrating that the company generates high returns on shareholder investment relative to the total asset base.
Valuation Assessment
Valuation multiples for Pediatrix Medical Group, Inc. show a trailing twelve-month P/E ratio of 10.15 and a forward P/E of 8.47. The difference between these two ratios implies that the market expects earnings growth in the future, as the forward multiple is lower than the trailing multiple, suggesting the stock is priced based on anticipated higher profitability rather than current earnings. The price-to-book ratio is 1.84, which indicates that the market values the company at a significant premium of 84% over its tangible book value, reflecting investor confidence in its intangible assets and future cash generation capabilities. Alternative valuation metrics include a price-to-sales ratio of 0.88 and an EV/EBITDA of 6.85, which together suggest that the company is trading at a reasonable valuation relative to its sales and earnings power compared to historical averages for healthcare facilities. Price action over the last year shows a 52-week high of $24.99 and a 52-week low of $11.84, placing the current trading environment within a wide historical range that allows for significant volatility based on market sentiment. The stock's beta is 0.79, indicating that the price volatility is less than the broader market, meaning the asset tends to move with less intensity than the overall market index during periods of fluctuation.
Growth & Income
Growth metrics for the company show a revenue decline of -1.7% year-over-year, contrasted with an earnings growth rate of 11.4% year-over-year. This divergence implies that earnings are growing faster than revenue, likely driven by operational efficiency improvements, cost control measures, or margin expansion rather than top-line volume increases. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all of its earnings back into the business to fund growth initiatives or strengthen the balance sheet rather than distributing cash to shareholders. The overall growth and income profile is characterized by a decoupling of top-line sales from earnings performance, resulting in a scenario where profitability expands even as revenue contracts, while the lack of a dividend yield shifts the total return expectation entirely toward capital appreciation and operational leverage.